Entera Bio Statistics
Total Valuation
Entera Bio has a market cap or net worth of $66.49 million. The enterprise value is $58.13 million.
Important Dates
The next estimated earnings date is Friday, March 27, 2026, after market close.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Entera Bio has 45.86 million shares outstanding. The number of shares has increased by 25.17% in one year.
| Current Share Class | 45.86M |
| Shares Outstanding | 45.86M |
| Shares Change (YoY) | +25.17% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 2.51% |
| Owned by Institutions (%) | 11.86% |
| Float | 31.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 536.23 |
| Forward PS | n/a |
| PB Ratio | 4.35 |
| P/TBV Ratio | 4.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 468.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.83, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.83 |
| Quick Ratio | 5.46 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -99.43% and return on invested capital (ROIC) is -60.93%.
| Return on Equity (ROE) | -99.43% |
| Return on Assets (ROA) | -53.80% |
| Return on Invested Capital (ROIC) | -60.93% |
| Return on Capital Employed (ROCE) | -68.35% |
| Weighted Average Cost of Capital (WACC) | 14.30% |
| Revenue Per Employee | $5,636 |
| Profits Per Employee | -$490,045 |
| Employee Count | 22 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Entera Bio has paid $14,000 in taxes.
| Income Tax | 14,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.33% in the last 52 weeks. The beta is 1.84, so Entera Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.84 |
| 52-Week Price Change | -40.33% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 2.03 |
| Relative Strength Index (RSI) | 47.68 |
| Average Volume (20 Days) | 230,952 |
Short Selling Information
| Short Interest | 101,784 |
| Short Previous Month | 99,052 |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.32% |
| Short Ratio (days to cover) | 0.36 |
Income Statement
In the last 12 months, Entera Bio had revenue of $124,000 and -$10.78 million in losses. Loss per share was -$0.24.
| Revenue | 124,000 |
| Gross Profit | n/a |
| Operating Income | -10.82M |
| Pretax Income | -10.77M |
| Net Income | -10.78M |
| EBITDA | -10.79M |
| EBIT | -10.82M |
| Loss Per Share | -$0.24 |
Full Income StatementBalance Sheet
The company has $8.57 million in cash and $211,000 in debt, with a net cash position of $8.36 million or $0.18 per share.
| Cash & Cash Equivalents | 8.57M |
| Total Debt | 211,000 |
| Net Cash | 8.36M |
| Net Cash Per Share | $0.18 |
| Equity (Book Value) | 15.23M |
| Book Value Per Share | 0.33 |
| Working Capital | 15.44M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.00 million and capital expenditures -$83,000, giving a free cash flow of -$7.09 million.
| Operating Cash Flow | -7.00M |
| Capital Expenditures | -83,000 |
| Free Cash Flow | -7.09M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -8,729.03% |
| Pretax Margin | -8,683.06% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Entera Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.17% |
| Shareholder Yield | -25.17% |
| Earnings Yield | -16.21% |
| FCF Yield | -10.66% |
Analyst Forecast
The average price target for Entera Bio is $10.00, which is 589.66% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 589.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Entera Bio has an Altman Z-Score of 11.83 and a Piotroski F-Score of 2.
| Altman Z-Score | 11.83 |
| Piotroski F-Score | 2 |
